HCW Biologics Inc. (HCWB) AI Stock Analysis

HCW Biologics Inc. is a biopharmaceutical company in the preclinical stage, specializing in the discovery and development of innovative immunotherapies targeting chronic, low-grade inflammation, and age-related diseases. The company's pipeline is anchored by HCW9218, an injectable immunotherapeutic designed for pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis. HCW Biologics also focuses on HCW9302, aimed at autoimmune conditions like alopecia areata and metabolic diseases. Additionally, the company is advancing HCW9201, a cell-based therapy currently in Phase II clinical trials for relapsed or refractory acute myeloid leukemia, alongside HCW9206 for acute myeloid leukemia treatment.

Between FY2021 and FY2025, revenue fluctuated before declining sharply, generating a 5-year revenue CAGR of -57.9%. Revenue grew 64.0% in FY2022 to $6.7M, but dropped 57.7% in FY2023 to $2.8M, fell 9.7% in FY2024 to $2.6M, and declined 97.9% in FY2025 to $54,232. Operating margin contracted from -326.1% in FY2021 to -20757.6% in FY2025, while net income registered at -$8.0M in FY2025 with an EPS of -$25.08. For the latest quarter ended June 30, 2026, quarterly revenue growth was 1969.7% year-over-year, contributing to trailing twelve-month revenue of $6.7M and a profit margin of -83.0%.

As of June 30, 2026, HCW Biologics held $741,324 in cash and short-term investments against total debt of $6.6M, resulting in net debt of $5.8M. The company's current ratio was 0.06, with a debt-to-equity ratio of 0.88 and shareholders' equity of $7.4M out of $26.8M in total assets. In FY2025, operating cash flow stood at -$13.4M and free cash flow was -$13.4M, with capital expenditures of $3.

HCW Biologics trades at a price-to-sales ratio of 0.4x and an enterprise value to revenue multiple of 1.3x, both below the median of its US-listed Healthcare peers, which show a price-to-sales multiple of 4.1x. The company's price-to-book ratio is 0.4x, with an enterprise value of $8.9M against a market capitalization of $2.8M. Over the past year, HCWB shares fell 94.9%, while the S&P 500 (SPY) returned 16.8%. Over a five-year period, HCWB declined 99.8% compared to an 83.0% gain for the benchmark.

Wall Street coverage consists of 1 Buy rating, with 0 Strong Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $48.00, representing an upside of 3771.0% over the last close of $1.24. For the fiscal year ending December 31, 2026, estimated EPS is -$28.32 on revenue of $6.7M. For the following fiscal year, 1 analyst projects revenue of $0 and an EPS of -$6.30. Over the last four quarters, HCWB beat EPS estimates once, and its next earnings date is November 13, 2026.

This page is an AI-written research summary of HCW Biologics Inc. (HCWB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HCWB income statement, HCWB balance sheet, HCWB key metrics, HCWB analyst forecast, HCWB chart. See the HCWB stock overview for the latest quote and news.